Table 1 Clinicopathological correlation of DAB2IP expression in ESCC
DAB2IP expression | |||
|---|---|---|---|
Variables | High | Low | P valuea |
Age (years) | 0.759 | ||
 ≤ 55b | 22 (24.2%) | 69 (75.8%) |  |
 > 55 | 13 (26.5%) | 36 (73.5%) |  |
Sex | 0.187 | ||
 Male | 19 (21.3%) | 70 (78.7%) |  |
 Female | 16 (31.4%) | 35 (68.6%) |  |
Location | 0.399 | ||
 Cervical/upper thoracic | 9 (31.0%) | 20 (69.0%) |  |
 Middle/lower thoracic | 26 (23.4%) | 85 (76.6%) |  |
WHO grade | < 0.001 | ||
 G1 | 21 (61.8%) | 13 (38.2%) |  |
 G2 | 9 (12.3%) | 64 (87.7%) |  |
 G3 | 5 (15.2%) | 28 (84.8%) |  |
Tumor size (cm) | < 0.001 | ||
 ≤ 5c | 23 (41.8%) | 32 (58.2%) |  |
 > 5 | 12 (14.1%) | 73 (85.9%) |  |
T status | 0.003 | ||
 T2/3 | 11 (14.9%) | 63 (85.1%) |  |
 T4 | 24 (36.4%) | 42 (63.6%) |  |
N status | < 0.001 | ||
 N0 | 20 (62.5%) | 12 (37.5%) |  |
 N1 | 15 (13.9%) | 93 (86.1%) |  |
M status | 0.017 | ||
 M0 | 27 (32.1%) | 57 (67.9%) |  |
 M1-lym | 8 (14.3%) | 48 (85.7%) |  |
CRT response | < 0.001 | ||
 CR | 18 (50.0%) | 18 (50.0%) |  |
 Non-CR | 17 (16.3%) | 87 (83.7%) |  |
Locoregional progression | 0.049 | ||
 Present | 10 (16.7%) | 50 (83.3%) |  |
 Absent | 25 (31.2%) | 55 (68.8%) |  |